Regulators Approve Merck and Eisai Combination Therapy for Kidney Cancer

Key Facts

1Regulators approved the combination of Merck's Welireg and Eisai's Lenvima for the treatment of kidney cancer.

Regulators approved the combination of Merck's Welireg and Eisai's Lenvima for the treatment of kidney cancer. Seeking Alpha reported that the approval covers advanced renal cell carcinoma, following clinical evaluations that demonstrated the efficacy of the combined drug regimen.

MRK closed at $148.08 on September 23, 2026, with the stock trading between a low of $146.89 and a high of $152.01 during that session. While price data was unavailable for Eisai (4523.T), the partnership reflects a strategic expansion of existing therapies into new oncology indications.